Möller, Sören http://orcid.org/0000-0003-0858-4269
Skjødt, Michael K. http://orcid.org/0000-0002-2109-8989
Yan, Lin
Abrahamsen, Bo http://orcid.org/0000-0002-2730-6080
Lix, Lisa M. http://orcid.org/0000-0001-8685-3212
McCloskey, Eugene V. http://orcid.org/0000-0003-0177-8140
Johansson, Helena http://orcid.org/0000-0002-7720-9297
Harvey, Nicholas C. http://orcid.org/0000-0002-8194-2512
Kanis, John A. http://orcid.org/0000-0002-3129-4326
Rubin, Katrine Hass http://orcid.org/0000-0001-5045-536X
Leslie, William D. http://orcid.org/0000-0002-1056-1691
Article History
Received: 11 May 2021
Accepted: 17 September 2021
First Online: 1 October 2021
Declarations
:
: The study was approved by the Health Research Ethics Board of the University of Manitoba.
: Not applicable.
: Not applicable.
: Michael K. Skjødt: educational grant, UCB; institutional research grant, UCB/Amgen. Eugene McCloskey: nothing to declare for the context of this paper, but numerous ad hoc consultancies/speaking honoraria and/or research funding from Amgen, Bayer, General Electric, GSK, Fresenius Kabi, Hologic, Lilly, Merck Research Labs, Novartis, Novo Nordisk, Nycomed, Ono, Pfizer, ProStrakan, Roche, Sanofi-Aventis, Servier, Tethys, UCB, and Warner-Chilcott. Nicholas Harvey: nothing to declare for the context of this paper, but has received consultancy/lecture fees/honoraria/grant funding from the Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Servier, Shire, UCB, Consilient Healthcare, Radius Health, Kyowa Kirin, and Internis Pharma. Bo Abrahamsen: institutional research contracts with Novartis, UCB, Kyowa-Kirin. Fees or honoraria from UCB, Amgen, Pharmacosmos. John Kanis: Professor Kanis led the team that developed FRAX as director of the WHO Collaborating Centre for Metabolic Bone Diseases; he has no financial interest in FRAX. William Leslie, Lisa Lix, Lin Yan, Helena Johansson, Sören Möller, and Katrine Hass Rubin: No conflicts of interest.